Precigen (PGEN) Share-based Compensation (2012 - 2026)
Precigen (PGEN) reported Share-based Compensation of $3.0 million for Q1 2026, up 12.29% year-over-year from $2.7 million in Q1 2025, and up 38.97% quarter-over-quarter from $2.2 million in Q4 2025.
Precigen (PGEN) Share-based Compensation (2012 - 2026) Analysis & Trends
Precigen (PGEN) has 15 years of Share-based Compensation data on file, last reported at $3.0 million in Q1 2026.
- Share-based Compensation for Q1 2026 came in at $3.0 million, up 12.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.2 million (up 17.02% YoY), and the FY2025 annual result was $10.9 million, up 14.73% from the prior year.
- Share-based Compensation advanced to $3.0 million in Q1 2026 per PGEN's latest filing, from $2.2 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $4.4 million in Q3 2025 and troughed at $1.6 million in Q2 2025.
- A 5-year average of $2.6 million and a median of $2.3 million in 2023 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2025: Share-based Compensation plunged 35.09% in 2022, then soared 112.91% in 2025.
- A 5-year view of Share-based Compensation shows it stood at $2.2 million in 2022, then climbed by 2.35% to $2.3 million in 2023, then advanced by 26.66% to $2.9 million in 2024, then retreated by 24.5% to $2.2 million in 2025, then soared by 38.97% to $3.0 million in 2026.
- Business Quant data shows PGEN's Share-based Compensation at $3.0 million in Q1 2026, $2.2 million in Q4 2025, and $4.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 305,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 26.47 Mn |
| 10 | Precigen | 1.27 Bn | 1.27 Bn | 20.69 Mn | 3.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.01 Mn |
| Mar 31, 2026 | 3.01 Mn |
| Dec 31, 2025 | 2.16 Mn |
| Dec 31, 2025 | 2.16 Mn |
| Sep 30, 2025 | 4.39 Mn |
| Sep 30, 2025 | 4.39 Mn |
| Jun 30, 2025 | 1.64 Mn |
| Jun 30, 2025 | 1.64 Mn |
| Mar 31, 2025 | 2.68 Mn |
| Mar 31, 2025 | 2.68 Mn |
| Dec 31, 2024 | 2.87 Mn |
| Dec 31, 2024 | 2.87 Mn |
| Sep 30, 2024 | 2.06 Mn |
| Sep 30, 2024 | 2.06 Mn |
| Jun 30, 2024 | 1.96 Mn |
| Jun 30, 2024 | 1.96 Mn |
| Mar 31, 2024 | 2.58 Mn |
| Mar 31, 2024 | 2.58 Mn |
| Dec 31, 2023 | 2.26 Mn |
| Dec 31, 2023 | 2.26 Mn |